Epigral Ltd

Epigral, a small-cap player in the specialty chemicals sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical performance. Recent assessment changes highlight concerns across multiple analytical parameters, signalling a cautious outlook for investors.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1400, reflecting a significant decline in its stock price over the past year. This development comes amid a backdrop of subdued financial performance and market conditions that have weighed on the company’s valuation.

Epigral, a player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1400, marking a significant price level for the stock. This development comes amid a backdrop of varied financial indicators and market conditions that have influenced the stock's performance over the past year.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1400, reflecting a significant decline in its stock price over the past year. This development comes amid a backdrop of subdued financial performance and market dynamics that have weighed on the company’s valuation.

Epigral, a key player in the Specialty Chemicals sector, has touched a new 52-week low of Rs.1400 today, marking a significant point in its recent market performance. This decline comes amid a broader context of subdued returns and financial metrics that reflect ongoing pressures on the company’s growth trajectory.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1400, marking a significant milestone in its recent trading history. This decline reflects ongoing challenges in the company’s financial performance and market positioning, despite a broader market environment showing resilience.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1400, reflecting a continuation of subdued market performance amid challenging financial indicators and sector dynamics.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1428, marking a significant decline in its stock price amid broader market movements and sector-specific pressures.

Epigral, a key player in the Specialty Chemicals sector, has reached a fresh 52-week low of Rs.1428, marking a significant price level as the stock continues to trade below all major moving averages amid broader market gains.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1428 today, marking a significant price level as the stock continues to trade below all major moving averages amid broader market gains.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1428, marking a significant decline in its stock price amid broader market movements and sector-specific pressures.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1428, marking a significant price level as the stock underperforms both its sector and broader market indices.

Epigral, a key player in the Specialty Chemicals sector, has reached a fresh 52-week low of Rs.1428, marking a significant decline in its stock price amid broader market movements and sector-specific pressures.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1428, reflecting a notable decline in its stock price amid broader market dynamics and company-specific performance factors.

Epigral, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1428 today, reflecting a notable decline in its stock price amid broader market dynamics and company-specific performance factors.

Epigral, a small-cap specialty chemicals company, has hit a new 52-week low, reflecting a significant decline in stock performance. Over the past year, the stock has dropped substantially, contrasting with broader market gains. Despite strong return metrics, recent financial results indicate challenges in growth and profitability.

Epigral, a small-cap specialty chemicals company, has hit a new 52-week low, reflecting a challenging performance with a 15.08% decline over the past week. The stock has consistently underperformed key moving averages and recorded a 31.98% drop over the past year, despite a strong return on capital employed.